Drugs / Lyophilized fecal microbiota transplantation capsules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05821010 | Mar 2023 → Feb 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lyophilized fecal microbiota transplantation capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05821010 ↗ |
| Known as | LFMCs | “This trial is a randomised, double-blind, placebo-controlled study investigating the therapeutic potential of lyophilised faecal microbiota capsules (LFMCs) in individuals with...” PMID 39788762 ↗ Jan 2025 |
| Modality | Other / unclassified | “lyophilised faecal microbiota capsules (LFMCs)” PMID 39788762 ↗ Jan 2025 |
| Route | Oral | “Oral administration (capsule)” NCT05821010 ↗ |